Japan’s MHLW Approves Boehringer’s Jascayd for IPF and PPF

Why It Matters

The approval introduces Japan’s first new oral therapy for IPF in over a decade, addressing a critical unmet need for convenient, long‑term treatment and potentially reshaping the pulmonary‑fibrosis market.

Key Takeaways

• Jascayd (nerandomilast) approved in Japan for IPF and PPF.
• First PDE4B inhibitor with antifibrotic, immunomodulatory action approved.
• Phase III FIBRONEER‑IPF met primary endpoint, slowing FVC decline.
• Pooled data showed 59% lower death risk versus placebo.
• Provides Japan's first new oral IPF therapy in over a decade.

Pulse Analysis

Idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) remain among the most lethal interstitial lung diseases, with median survival often under five years. Until now, Japan has relied on inhaled antifibrotics and limited intravenous options, leaving a gap for convenient oral agents. Boehringer Ingelheim’s Jascayd (nerandomilast) – a phosphodiesterase 4B inhibitor – received approval from the Ministry of Health, Labour and Welfare, marking the country’s fourth jurisdiction to authorize the drug and the first new IPF treatment in more than a decade.

The approval rests on the Phase III FIBRONEER‑IPF and FIBRONEER‑ILD trials, which demonstrated a statistically significant slowdown in forced vital capacity (FVC) decline over 52 weeks compared with placebo. Although secondary endpoints such as quality‑of‑life measures were not met, a pooled analysis revealed a 59% reduction in mortality risk for patients receiving the 18 mg dose without background therapy. Nerandomilast’s dual antifibrotic and immunomodulatory profile, combined with a favorable safety record, positions it as a viable long‑term oral option for patients struggling with adherence to injectable regimens.

From a commercial perspective, Jascayd opens a new revenue stream for Boehringer in the high‑growth pulmonary market, where global sales of antifibrotics are projected to exceed $10 billion by 2030. The Japanese launch may serve as a springboard for broader regulatory submissions in the United States and Europe, where unmet demand for oral IPF therapies is equally acute. Moreover, Boehringer’s recent partnership with Zai Lab on DLL3‑targeted therapies underscores a strategic push into oncology, suggesting the company will leverage its clinical expertise across multiple fibrotic and oncologic indications.